Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price objective upped by investment analysts at HC Wainwright from $54.00 to $105.00 in a research report issued on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 27.47% from the stock’s previous close.

Several other equities research analysts also recently issued reports on the stock. Roth Capital set a $82.00 price objective on shares of Madrigal Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 30th. JMP Securities raised their price objective on shares of Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the stock an “outperform” rating in a research report on Friday, October 13th. Finally, Evercore ISI began coverage on shares of Madrigal Pharmaceuticals in a research report on Friday, September 22nd. They set an “outperform” rating and a $65.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $113.00.

Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) opened at $82.37 on Wednesday. Madrigal Pharmaceuticals has a 1 year low of $13.09 and a 1 year high of $101.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.11. equities analysts predict that Madrigal Pharmaceuticals will post -2.57 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in shares of Madrigal Pharmaceuticals during the third quarter worth approximately $100,000. New York State Common Retirement Fund bought a new position in shares of Madrigal Pharmaceuticals during the second quarter worth approximately $109,000. California State Teachers Retirement System bought a new position in shares of Madrigal Pharmaceuticals during the second quarter worth approximately $117,000. TIAA CREF Investment Management LLC bought a new position in shares of Madrigal Pharmaceuticals during the second quarter worth approximately $120,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Madrigal Pharmaceuticals during the second quarter worth approximately $179,000. 21.40% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Madrigal Pharmaceuticals (MDGL) PT Raised to $105.00 at HC Wainwright” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/12/08/madrigal-pharmaceuticals-mdgl-pt-raised-to-105-00-at-hc-wainwright.html.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).

Receive News & Stock Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.